Cargando…

Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile

Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilera, Ximena, González, Claudia, Apablaza, Mauricio, Rubilar, Paola, Icaza, Gloria, Ramírez-Santana, Muriel, Pérez, Claudia, Cortes, Lina Jimena, Núñez-Franz, Loreto, Quezada-Gaete, Rubén, Castillo-Laborde, Carla, Correa, Juan, Said, Macarena, Hormazábal, Juan, Vial, Cecilia, Vial, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322351/
https://www.ncbi.nlm.nih.gov/pubmed/35891166
http://dx.doi.org/10.3390/vaccines10071002
_version_ 1784756281807994880
author Aguilera, Ximena
González, Claudia
Apablaza, Mauricio
Rubilar, Paola
Icaza, Gloria
Ramírez-Santana, Muriel
Pérez, Claudia
Cortes, Lina Jimena
Núñez-Franz, Loreto
Quezada-Gaete, Rubén
Castillo-Laborde, Carla
Correa, Juan
Said, Macarena
Hormazábal, Juan
Vial, Cecilia
Vial, Pablo
author_facet Aguilera, Ximena
González, Claudia
Apablaza, Mauricio
Rubilar, Paola
Icaza, Gloria
Ramírez-Santana, Muriel
Pérez, Claudia
Cortes, Lina Jimena
Núñez-Franz, Loreto
Quezada-Gaete, Rubén
Castillo-Laborde, Carla
Correa, Juan
Said, Macarena
Hormazábal, Juan
Vial, Cecilia
Vial, Pablo
author_sort Aguilera, Ximena
collection PubMed
description Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.
format Online
Article
Text
id pubmed-9322351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93223512022-07-27 Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile Aguilera, Ximena González, Claudia Apablaza, Mauricio Rubilar, Paola Icaza, Gloria Ramírez-Santana, Muriel Pérez, Claudia Cortes, Lina Jimena Núñez-Franz, Loreto Quezada-Gaete, Rubén Castillo-Laborde, Carla Correa, Juan Said, Macarena Hormazábal, Juan Vial, Cecilia Vial, Pablo Vaccines (Basel) Brief Report Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access. MDPI 2022-06-23 /pmc/articles/PMC9322351/ /pubmed/35891166 http://dx.doi.org/10.3390/vaccines10071002 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Aguilera, Ximena
González, Claudia
Apablaza, Mauricio
Rubilar, Paola
Icaza, Gloria
Ramírez-Santana, Muriel
Pérez, Claudia
Cortes, Lina Jimena
Núñez-Franz, Loreto
Quezada-Gaete, Rubén
Castillo-Laborde, Carla
Correa, Juan
Said, Macarena
Hormazábal, Juan
Vial, Cecilia
Vial, Pablo
Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title_full Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title_fullStr Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title_full_unstemmed Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title_short Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
title_sort immunization and sars-cov-2 antibody seroprevalence in a country with high vaccination coverage: lessons from chile
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322351/
https://www.ncbi.nlm.nih.gov/pubmed/35891166
http://dx.doi.org/10.3390/vaccines10071002
work_keys_str_mv AT aguileraximena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT gonzalezclaudia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT apablazamauricio immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT rubilarpaola immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT icazagloria immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT ramirezsantanamuriel immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT perezclaudia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT corteslinajimena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT nunezfranzloreto immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT quezadagaeteruben immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT castillolabordecarla immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT correajuan immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT saidmacarena immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT hormazabaljuan immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT vialcecilia immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile
AT vialpablo immunizationandsarscov2antibodyseroprevalenceinacountrywithhighvaccinationcoveragelessonsfromchile